• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bolt Biotherapeutics Inc (NQ: BOLT )

    0.7591 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 904
    Open 0.7591
    Bid (Size) 0.7551 (29)
    Ask (Size) 0.7700 (1)
    Prev. Close 0.7591
    Today's Range 0.7591 - 0.7591
    52wk Range 0.7341 - 1.680
    Shares Outstanding 8,709,974
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows
    Explore key stocks with analyst uncertainty to avoid amid contrasting global market highs and risky downgrades. 
    Via InvestorPlace
    Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga

    Performance

    YTD
    -34.56%
    -34.56%
    1 Month
    -36.75%
    -36.75%
    3 Month
    -37.78%
    -37.78%
    6 Month
    -15.66%
    -15.66%
    1 Year
    -49.73%
    -49.73%

    More News

    Read More
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today
    Via Benzinga
    Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Pacira Appoints Frank D. Lee as Chief Executive Officer
    From Pacira BioSciences
    Via GlobeNewswire
    Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
    Via ACCESSWIRE
    Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
    From Bolt Biotherapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.